Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
ABEO Quote, Financials, Valuation and Earnings
Last price:
$5.19
Seasonality move
:
322.32%
Day range:
$5.05 - $5.32
52-week range:
$3.93 - $7.54
Dividend yield:
0%
P/E ratio:
4.54x
P/S ratio:
715.16x
P/B ratio:
1.67x
Volume:
1.7M
Avg. volume:
1.2M
1-year change:
-9.73%
Market cap:
$286.7M
Revenue:
--
EPS (TTM):
$1.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
$5.6M | -$0.34 | -97.62% | -57.23% | $20.64 |
|
ATOS
Atossa Therapeutics, Inc.
|
-- | -$1.14 | -- | -1919.23% | $80.00 |
|
CLCS
Cell Source, Inc.
|
-- | -- | -- | -- | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
$1.5M | -$1.00 | -9.83% | -30.49% | $53.36 |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$1.5M | -$0.70 | 3650% | -11.09% | $11.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
$5.29 | $20.64 | $286.7M | 4.54x | $0.00 | 0% | 715.16x |
|
ATOS
Atossa Therapeutics, Inc.
|
$4.42 | $80.00 | $38.1M | -- | $0.00 | 0% | -- |
|
CLCS
Cell Source, Inc.
|
$0.8500 | -- | $38.3M | -- | $0.00 | 0% | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
$23.54 | $53.36 | $1.6B | -- | $0.00 | 0% | 601.06x |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$2.06 | $11.00 | $7.6M | -- | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $5.50 | $40.2M | -- | $0.00 | 0% | 4.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -1.035 | 8.71% | 9.35x |
|
ATOS
Atossa Therapeutics, Inc.
|
-- | 0.662 | -- | 6.32x |
|
CLCS
Cell Source, Inc.
|
-- | -0.372 | -- | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
0.44% | 1.179 | 0.15% | 12.42x |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
1.77% | 0.329 | 4.23% | 7.51x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
ATOS
Atossa Therapeutics, Inc.
|
-$4K | -$9.3M | -47.46% | -47.46% | -- | -$6M |
|
CLCS
Cell Source, Inc.
|
-- | -$831.6K | -- | -- | -- | -$639K |
|
CLDX
Celldex Therapeutics, Inc.
|
-$824K | -$73.6M | -32.02% | -32.17% | -8747.53% | -$49.1M |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
-$38.2K | -$2.5M | -34.13% | -34.44% | 82.56% | -$1.3M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Abeona Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ABEO or ATOS?
Atossa Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of --. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M -
What do Analysts Say About ABEO or ATOS?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 290.22%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $80.00 which suggests that it could grow by 1455.43%. Given that Atossa Therapeutics, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 ATOSAtossa Therapeutics, Inc.3 0 0 -
Is ABEO or ATOS More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 1.364, suggesting its more volatile than the S&P 500 by 36.379%.
-
Which is a Better Dividend Stock ABEO or ATOS?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or ATOS?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Atossa Therapeutics, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.54x while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 715.16x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M
-
Which has Higher Returns ABEO or CLCS?
Cell Source, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of --. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Cell Source, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M CLCSCell Source, Inc.-- -$0.04 -- -
What do Analysts Say About ABEO or CLCS?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 290.22%. On the other hand Cell Source, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Abeona Therapeutics, Inc. has higher upside potential than Cell Source, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Cell Source, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 CLCSCell Source, Inc.0 0 0 -
Is ABEO or CLCS More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Cell Source, Inc. has a beta of -225.097, suggesting its less volatile than the S&P 500 by 22609.671%.
-
Which is a Better Dividend Stock ABEO or CLCS?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cell Source, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Cell Source, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or CLCS?
Abeona Therapeutics, Inc. quarterly revenues are --, which are larger than Cell Source, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Cell Source, Inc.'s net income of -$1.4M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.54x while Cell Source, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 715.16x versus -- for Cell Source, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M CLCSCell Source, Inc.-- -- -- -$1.4M
-
Which has Higher Returns ABEO or CLDX?
Celldex Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -7753.43%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M -
What do Analysts Say About ABEO or CLDX?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 290.22%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.36 which suggests that it could grow by 126.67%. Given that Abeona Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 CLDXCelldex Therapeutics, Inc.12 2 0 -
Is ABEO or CLDX More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.242, suggesting its more volatile than the S&P 500 by 24.184%.
-
Which is a Better Dividend Stock ABEO or CLDX?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or CLDX?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.54x while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 715.16x versus 601.06x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M
-
Which has Higher Returns ABEO or KPRX?
Kiora Pharmaceuticals, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of 84.08%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M -
What do Analysts Say About ABEO or KPRX?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 290.22%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 433.98%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 KPRXKiora Pharmaceuticals, Inc.0 0 0 -
Is ABEO or KPRX More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.819, suggesting its less volatile than the S&P 500 by 181.948%.
-
Which is a Better Dividend Stock ABEO or KPRX?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or KPRX?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.54x while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 715.16x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K
-
Which has Higher Returns ABEO or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -316.61%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About ABEO or PSTV?
Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 290.22%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABEOAbeona Therapeutics, Inc.6 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is ABEO or PSTV More Risky?
Abeona Therapeutics, Inc. has a beta of 1.175, which suggesting that the stock is 17.515% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock ABEO or PSTV?
Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABEO or PSTV?
Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.54x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 715.16x versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M PSTVPlus Therapeutics, Inc.4.69x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 2.23% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.38% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is up 0.8% over the past day.
